pirfenidone

InterMune expects a final decision within three months, and the company is preparing to launch Esbriet, also known as pirfenidone, in Europe, starting in Germany and

The Seattle Times 2010

InterMune said it expects a final decision in two to three months, and the company said it is preparing to launch Esbriet, also known as pirfenidone, in Europe, starting in Germany and France.

InterMune gets EU recommendation on lung drug - Yahoo! Finance 2010

WASHINGTON - Shares of drug developer InterMune Inc. surged Friday after federal health officials posted their review of the experimental drug pirfenidone, which is designed to treat a rare lung disease.

Gaea Times (by Simple Thoughts) Breaking News and incisive views 24/7 Matthew Perrone 2010

InterMune expects a final decision within three months, and the company is preparing to launch Esbriet, also known as pirfenidone, in Europe, starting in Germany and

Ahead of the Bell: Analyst upgrades InterMune - Yahoo! Finance 2010

InterMune's Esbriet, also known by its scientific name pirfenidone, was rejected the U.S.

InterMune: EU to OK Esbriet Lung Drug - TheStreet 2010

Esbriet, also known as pirfenidone, would have been the first drug approved in the United

Philadelphia Business News - Local Philadelphia News | The Philadelphia Business Journal 2010

Maryland: Diabetics who wear insulin pumps appear more likely to experience problems from improper use than a device defect, members of a U.S. government advisory health officials posted their review of the experimental drug pirfenidone, which is designed to Drug Administration panel of experts reviews a key lung drug candidate.

WN.com - Business News 2010

The medication, known as pirfenidone, is made by InterMune Inc. and would be used to treat idiopathic pulmonary fibrosis.

Medlogs - Recent stories 2010

The European Commission could act on the recommendation in two to three months, InterMune said, opening the door for the drug, called pirfenidone and branded as Esbriet, to be sold in the 27 countries of the European Union.

InterMune lung drug nears EU approval | San Francisco Business Times 2010

The vote of confidence from the FDA's Pulmonary-Allergy Drugs Advisory Committee sparked buyout speculation on Wall Street, which sees gold in orphan drugs, such as pirfenidone, with the potential to sell to niche markets for high prices and retain extended patent protection.

SeekingAlpha.com: Home Page The Burrill Report 2010